InvestorsHub Logo
Followers 73
Posts 6205
Boards Moderated 0
Alias Born 05/01/2011

Re: None

Tuesday, 07/02/2019 9:34:47 AM

Tuesday, July 02, 2019 9:34:47 AM

Post# of 425038
I guess the only remaining possible resistance now is the minor chance of another secondary -- justified by anticipation of a big marketing rollout.

BUT.

Cashflow positive now... more cashflow positive coming... and with Europe filing signalled for Q4 2019, you gotta think that means a Euro deal if GIA. And that, after FDA approval, would have to come with BLOCKBUSTER payments ($bn's upfront, giant milestones and royalties, etc.)

All things considered, the argument for an offering is rather weak.

“The trick is in what one emphasizes. We either make ourselves miserable, or we make ourselves happy. The amount of work is the same.” Carlos Castaneda

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News